BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38007223)

  • 1. Interval colorectal cancers after negative faecal immunochemical test in the New Zealand Bowel Screening Pilot.
    Saw KS; Sexton K; Frankish P; Hulme-Moir M; Bissett I; Parry S
    BMJ Open Gastroenterol; 2023 Nov; 10(1):. PubMed ID: 38007223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality.
    Clark GR; Godfrey T; Purdie C; Strachan J; Carey FA; Fraser CG; Steele RJ
    J Med Screen; 2024 Mar; 31(1):21-27. PubMed ID: 37469171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-risk symptoms and quantitative faecal immunochemical test accuracy: Systematic review and meta-analysis.
    Pin Vieito N; Zarraquiños S; Cubiella J
    World J Gastroenterol; 2019 May; 25(19):2383-2401. PubMed ID: 31148909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.
    Tran TN; Peeters M; Hoeck S; Van Hal G; Janssens S; De Schutter H
    Br J Cancer; 2022 Apr; 126(7):1091-1099. PubMed ID: 35022524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do faecal test-based colorectal cancer screening pilots provide data that are reflected in subsequent programmes? Evidence from interval cancer proportions.
    Clark GR; Steele RJ; Fraser CG
    Ann Clin Biochem; 2022 Nov; 59(6):450-452. PubMed ID: 36031942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment.
    Ribe SG; Botteri E; Løberg M; Randel KR; Kalager M; Nilsen JA; Gulichsen EH; Holme Ø
    Int J Cancer; 2023 Apr; 152(7):1414-1424. PubMed ID: 36346118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One or two faecal immunochemical tests in an organised population-based colorectal cancer screening programme in Murcia (Spain).
    Tourne-Garcia C; Perez-Riquelme F; Monteagudo-Piqueras O; Fraser CG; Yepes-Garcia P
    J Med Screen; 2022 Dec; 29(4):231-240. PubMed ID: 35578555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: A community-based cohort study.
    Pin-Vieito N; García Nimo L; Bujanda L; Román Alonso B; Gutierrez-Stampa MÁ; Aguilar-Gama V; Portillo I; Cubiella J
    United European Gastroenterol J; 2021 Mar; 9(2):256-267. PubMed ID: 32778002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy.
    Senore C; Zappa M; Campari C; Crotta S; Armaroli P; Arrigoni A; Cassoni P; Colla R; Fracchia M; Gili F; Grazzini G; Lolli R; Menozzi P; Orione L; Polizzi S; Rapi S; Riggi E; Rubeca T; Sassatelli R; Visioli C; Segnan N
    Gut; 2020 Mar; 69(3):523-530. PubMed ID: 31455608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
    Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
    United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round.
    Digby J; Fraser CG; Carey FA; Diament RH; Balsitis M; Steele RJ
    J Med Screen; 2017 Jun; 24(2):62-68. PubMed ID: 27370211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison with first round findings of faecal haemoglobin concentrations and clinical outcomes in the second round of a biennial faecal immunochemical test based colorectal cancer screening programme.
    Clark GR; Fraser CG; Strachan JA; Steele RJ
    J Med Screen; 2022 Dec; 29(4):249-254. PubMed ID: 35747907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.
    Ribbing Wilén H; Blom J
    J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
    Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
    Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.